Last reviewed · How we verify
NCT06232616
Vitrectomy Combined With Intravitreal Dexamethasone Implant for Idiopathic Epiretinal Membrane With Macular Oedema
NA trial testing vitrectomy combined with intravitreal dexamethasone implant in Epiretinal Membrane in 20 participants. Enrolling by invitation.
30 November 2025
Quick facts
| Lead sponsor | Shanghai Eye Disease Prevention and Treatment Center |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 11 March 2024 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- vitrectomy combined with intravitreal dexamethasone implant
Conditions studied
- Epiretinal Membrane — all drugs for Epiretinal Membrane →
Sponsor
Shanghai Eye Disease Prevention and Treatment Center — full company profile →
Who can join
40 and older, any sex, with Epiretinal Membrane. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the efficacy and safety of 25-gauge pars plana vitrectomy combined with intravitreal dexamethasone implant for the treatment of idiopathic epiretinal membrane with cystoid macular oedema. The main questions it aims to answer are: * mean changes in best corrected visual acuity and central macular thickness from baseline to post-operative 24 weeks * mean change in proportion of cystoid macular oedema area from baseline to post-operative 24 weeks * intraocular pressure throughout postoperative 24 weeks * concentrations of inflammatory factors in vitreous samples Participants will undergo a standard three-port 25-gauge pars plana vitrectomy and epiretinal membrane peeling combined with phacoemulsification, aspiration, and intraocular lens implantation. The dexamethasone implant will be injected into the vitreous cavity at the end of the operation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06232616
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epiretinal Membrane
Currently open trials in the same condition.
- NCT07019896 — Minimal Vitrectomy Surgery for Epiretinal Membrane · NA · recruiting
- NCT06719739 — Functional IOL Implantation in Patients With Epiretinal Membrane · NA · recruiting
- NCT06948851 — New Postoperative Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling Due to Epiretinal Membranes · active not recruiting
- NCT05145491 — Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM · NA · recruiting
- NCT04306718 — Cultivation of Hyalocytes From ILM and ERM Samples: a Pilot Study · NA · active not recruiting
Other Shanghai Eye Disease Prevention and Treatment Center trials
Trials by the same sponsor.
- NCT07535658 — Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control · NA · not yet recruiting
- NCT07514039 — Photolithography Microstructure Myopia Management Lenses in Preventing and Controlling Myopia in Children and Adolescent · NA · enrolling by invitation
- NCT07312214 — LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia · NA · recruiting
- NCT07284147 — 3D Designed Defocus Lenses on Myopia Control in Children and Adolescents · NA · enrolling by invitation
- NCT07120737 — Efficacy and Safety of Spectacle Lenses With H.A.L.T. MAX Technology on High Myopia Control in Children and Adolescents · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06232616 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Eye Disease Prevention and Treatment Center
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06232616.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing